Guest: Michael Kotsanis
Presenter: Wayne Bucklar
Guest Bio: Michael Kotsanis is the Chief Executive Officer & Managing Director of Acrux. Michael commenced as CEO and Managing Director of Acrux in November, 2014. He has over 25 years of experience in the pharmaceutical industry and has significant senior Ieadership experience across the global pharmaceutical markets. Michael was formally the Chief Commercial Officer for Synthon Holding BV, a specialty pharmaceutical company based in The Netherlands, a position he held from mid-2010.
Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira, the global leader in generic injectable pharmaceuticals. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he served as President Asia Pacific from 2002. He joined Mayne following their acquisition of Faulding Pharmaceuticals in 2001, where he held responsibility for commercial activities in Australia and New Zealand. Prior to Faulding, Michael held a variety of sales and marketing positions with Boehringer Ingelheim over an 11 year period. Michael earned a bachelor’s degree in science from Monash University, and a master’s degree in business from the University of Technology, Sydney.
Segment overview: In today’s Health Supplier Segment, we are joined by Acrux Chief Executive Officer and Managing Director Michael Kotsanis to talk about their company’s background and drug delivery solutions. Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless PatchTM, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. They also have a range of generic and patent-preferred products that are currently in development.